Quantitative MRI for Myelofibrosis
ConditionMyelofibrosis
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18-99
SponsorUniversity of Michigan Rogel Cancer Center
About this trial
This study is for the development and validation of functional magnetic resonance imaging (MRI) parameters as biomarkers for analyzing extent of disease and quantifying response to treatment in patients with myelofibrosis.
Eligibility criteria
Qualifiers
Male /female subjects over the age of 18
Diagnosis of primary myelofibrosis, post-polycythemia vera myelofibrosis, or post-essential thrombocythemia myelofibrosis.
No contraindications to MRI
Able to undergo MRI without anesthesia
Disqualifiers
Patients with pacemakers or other implanted magnetic devices that may malfunction or move because of the strong magnetic field inside the MRI room and scanner.
Any prior adverse event associated with MRI that is not related to injection of contrast agents or other medicines.
Trial design
Treatments tested in this trial
- T1 Weighted MRI (magnetic resonance imaging)
Treatment groups
192 Participants
are divided into 1 treatment groupSponsors and collaborators
University of Michigan Rogel Cancer Center
Lead sponsor
Sanofi
Collaborator
National Cancer Institute (NCI)
Collaborator
Source ClinicalTrials.gov